basal insulin with glp 1 Adding a GLP-1 receptor agonist was not associated a lower likelihood of discontinuing existing therapy among veterans with type 2 diabetes compared with other glucose-lowering agents, a target emulation GLP-1 receptor agonist use does

The irreversible nature of blindness eliminates defendants arguments about temporary side effects or symptom resolution, creating cleaner liability theories focused solely on the failure to warn about a devastating permanent injury

These agents show promise in reversing endothelial dysfunction, suppressing inflammatory cytokines, and protecting organs from oxidative stress-induced damage

The SURMOUNT trial program provides extensive data on what tirzepatide achieves without any additional weight loss medication: 5 mg dose: 15.0% average weight loss at 72 weeks 10 mg dose: 19.5% average weight loss at 72 weeks 15 mg dose: 20.9% average weight loss at 72 weeks At 15 mg, 56.1% of participants lost at least 20% of body weight At 15 mg, 38.7% of participants lost at least 25% of body weight These numbers are remarkable

Plan monitoring includes symptom logs, ultrasound timing, and repeat labs to measure effect and safety